pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Lead Program · news · pharmadog
← back to Lead Program
News mentioning Lead Program
38
stories
2d
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
11d
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
fiercebiotech
20d
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
fiercebiotech
26d
NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand
endpoints
26d
A new immuno-oncology play raises $225M for a next-generation drug
biopharma dive
Sep 1, 26
Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'
endpoints
Aug 31, 26
Lilly adds to immune drug pipeline with $2.9B Merida buyout
biopharma dive
Aug 28, 26
AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond
fiercebiotech
Aug 26, 26
An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies
endpoints
Aug 24, 26
Capricor’s Duchenne therapy has new life after FDA grants 3-month extension
biospace
Aug 21, 26
Capricor investor calls for change as company awaits decision on Duchenne candidate
biospace
Aug 21, 26
Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug
fiercebiotech
Aug 17, 26
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
fiercebiotech
Aug 14, 26
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
Aug 12, 26
Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
fiercebiotech
Aug 10, 26
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
biopharma dive
Aug 10, 26
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
biopharma dive
Aug 10, 26
Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program
fiercebiotech
Aug 5, 26
Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees
biospace
Aug 5, 26
Lilly drops another gene therapy trial from $1B Prevail buyout
fiercebiotech
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Aug 4, 26
STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
stat
Jul 30, 26
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
Jul 30, 26
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
Jul 30, 26
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
Jul 29, 26
Caldera, Vidya add to recent flurry of biotech mergers
biopharma dive
Jul 24, 26
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
Jul 20, 26
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
Jul 17, 26
Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M deal
fiercebiotech
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
← prev
page 1 of 2
next →
